Surface Oncology

Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388). Headquartered in Cambridge, Massachusetts, Surface Oncology leverages proprietary insights into novel immunotherapy targets and emerging fields of cancer immunobiology to advance next-generation cancer immunotherapy approaches.